Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586399 | 1.00 | CASP3 (0.49) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL13256282 | 0.87 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL14586400 | 0.87 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL13382807 | 0.87 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL7163160 | 0.86 | CASP3 (0.61) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL13382806 | 0.86 | CASP3 (0.61) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL5055623 | 0.85 | CASP3 (0.45) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL19157353 | 0.85 | TLR2 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL19529036 | 0.85 | TLR2 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL13863441 | 0.84 | KMT2A (0.53) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | PTPRCAP, PTPRC, PTPA | CASP3 3800/4885MDM4 1983/4885TP53 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.